FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094706812> ?p ?o ?g. }

• W3094706812 endingPage "367" @default.
• W3094706812 startingPage "355" @default.
• W3094706812 abstract "We investigated the association of peripheral blood inflammatory markers with overall survival (OS) in pembrolizumab treated advanced non-small cell lung cancer (aNSCLC) patients with programmed death ligand 1 (PD-L1) expression ≥50%. Clinical risk factors for development of immune-related adverse events (irAE) were also explored.aNSCLC patients with high PD-L1 expression receiving pembrolizumab monotherapy outside of clinical trials were identified retrospectively. All patients were treated at one of six British Columbia Cancer clinics between August 2017 and June 2019. Patients were dichotomized using baseline neutrophil-to-lymphocyte ratio (NLR, </≥6.4) and platelet-to-lymphocyte ratio (PLR, </≥441.8). Factors associated with OS were assessed with Cox proportional hazard models. Logistic regression models were utilized in landmark analysis of risk factors for irAE.Among 220 patients, median age was 70.0 years, 55.0% were female, 40.5% had baseline Eastern Cooperative Oncology Group performance status (ECOG PS) 2/3, and 95.5% received frontline pembrolizumab. Median OS for the cohort was 11.8 months (95% CI: 8.7-15.4). On multivariable analysis, baseline NLR ≥6.4 [hazard ratio (HR): 2.31, 95% confidence interval (CI): 1.46-3.64, P<0.001], baseline PLR ≥441.8 (HR: 2.03, 95% CI 1.22-3.37, P=0.006), and pre-treatment ECOG PS 2/3 (HR: 2.19, 95% CI: 1.48-3.26, P<0.001) were associated with worse OS. The incidence of any grade irAE and irAE grade ≥3 were 40.5% and 12.3%, respectively. ECOG PS 2/3 (vs. 0/1) patients were at 3.76-fold higher risk of developing an irAE by the 8-month landmark (P=0.002).High NLR and PLR were associated with shorter OS in a cohort of patients receiving largely frontline pembrolizumab for aNSCLC in routine practice. ECOG PS 2/3 was associated with higher risk of developing an irAE. Given that NLR and PLR values are easily obtainable, prospective studies are warranted to confirm their prognostic significance in this patient population and explore a predictive utility." @default.
• W3094706812 created "2020-11-09" @default.
• W3094706812 creator A5005897790 @default.
• W3094706812 creator A5006264564 @default.
• W3094706812 creator A5013638354 @default.
• W3094706812 creator A5028859301 @default.
• W3094706812 creator A5034551860 @default.
• W3094706812 creator A5038320933 @default.
• W3094706812 creator A5042083973 @default.
• W3094706812 creator A5051067770 @default.
• W3094706812 creator A5070495365 @default.
• W3094706812 creator A5075020691 @default.
• W3094706812 creator A5076880709 @default.
• W3094706812 creator A5081083820 @default.
• W3094706812 creator A5085426335 @default.
• W3094706812 date "2021-01-01" @default.
• W3094706812 modified "2023-10-01" @default.
• W3094706812 title "Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab" @default.
• W3094706812 cites W1598439963 @default.
• W3094706812 cites W1722843651 @default.
• W3094706812 cites W1971211622 @default.
• W3094706812 cites W1981049999 @default.
• W3094706812 cites W1982488143 @default.
• W3094706812 cites W1982906652 @default.
• W3094706812 cites W2014229457 @default.
• W3094706812 cites W2020016182 @default.
• W3094706812 cites W2067971776 @default.
• W3094706812 cites W2118278569 @default.
• W3094706812 cites W2198093519 @default.
• W3094706812 cites W2289841322 @default.
• W3094706812 cites W2320872877 @default.
• W3094706812 cites W2324143682 @default.
• W3094706812 cites W2331849216 @default.
• W3094706812 cites W2560367415 @default.
• W3094706812 cites W2561156916 @default.
• W3094706812 cites W2572174216 @default.
• W3094706812 cites W2581283430 @default.
• W3094706812 cites W2737656823 @default.
• W3094706812 cites W2772599579 @default.
• W3094706812 cites W2783897381 @default.
• W3094706812 cites W2784283849 @default.
• W3094706812 cites W2792273180 @default.
• W3094706812 cites W2796582438 @default.
• W3094706812 cites W2802496191 @default.
• W3094706812 cites W2892640821 @default.
• W3094706812 cites W2897062681 @default.
• W3094706812 cites W2900661972 @default.
• W3094706812 cites W2904366723 @default.
• W3094706812 cites W2906009141 @default.
• W3094706812 cites W2908431216 @default.
• W3094706812 cites W2910245285 @default.
• W3094706812 cites W2925446385 @default.
• W3094706812 cites W2941271487 @default.
• W3094706812 cites W2943701399 @default.
• W3094706812 cites W2954766060 @default.
• W3094706812 cites W2974280214 @default.
• W3094706812 cites W2977484833 @default.
• W3094706812 cites W2993964118 @default.
• W3094706812 cites W2999687281 @default.
• W3094706812 doi "https://doi.org/10.21037/tlcr-20-541" @default.
• W3094706812 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7867765" @default.
• W3094706812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33569318" @default.
• W3094706812 hasPublicationYear "2021" @default.
• W3094706812 type Work @default.
• W3094706812 sameAs 3094706812 @default.
• W3094706812 citedByCount "21" @default.
• W3094706812 countsByYear W30947068122021 @default.
• W3094706812 countsByYear W30947068122022 @default.
• W3094706812 countsByYear W30947068122023 @default.
• W3094706812 crossrefType "journal-article" @default.
• W3094706812 hasAuthorship W3094706812A5005897790 @default.
• W3094706812 hasAuthorship W3094706812A5006264564 @default.
• W3094706812 hasAuthorship W3094706812A5013638354 @default.
• W3094706812 hasAuthorship W3094706812A5028859301 @default.
• W3094706812 hasAuthorship W3094706812A5034551860 @default.
• W3094706812 hasAuthorship W3094706812A5038320933 @default.
• W3094706812 hasAuthorship W3094706812A5042083973 @default.
• W3094706812 hasAuthorship W3094706812A5051067770 @default.
• W3094706812 hasAuthorship W3094706812A5070495365 @default.
• W3094706812 hasAuthorship W3094706812A5075020691 @default.
• W3094706812 hasAuthorship W3094706812A5076880709 @default.
• W3094706812 hasAuthorship W3094706812A5081083820 @default.
• W3094706812 hasAuthorship W3094706812A5085426335 @default.
• W3094706812 hasBestOaLocation W30947068121 @default.
• W3094706812 hasConcept C121608353 @default.
• W3094706812 hasConcept C126322002 @default.
• W3094706812 hasConcept C143998085 @default.
• W3094706812 hasConcept C207103383 @default.
• W3094706812 hasConcept C2776256026 @default.
• W3094706812 hasConcept C2777701055 @default.
• W3094706812 hasConcept C2777761686 @default.
• W3094706812 hasConcept C2780057760 @default.
• W3094706812 hasConcept C44249647 @default.
• W3094706812 hasConcept C50382708 @default.
• W3094706812 hasConcept C71924100 @default.
• W3094706812 hasConcept C72563966 @default.
• W3094706812 hasConcept C90924648 @default.
• W3094706812 hasConceptScore W3094706812C121608353 @default.

• next